Ainos, Inc. reported its Q1 2026 results after the close on May 13, and the print arrives at an interesting inflection point — short sellers have been pulling back sharply for weeks, even as borrow costs remain elevated.
The Q1 numbers show EPS of -$0.41, a marked improvement from -$1.05 a year ago. Revenue came in at $161,000, up from $106,207 in the prior-year period. The company also used its earnings release to highlight continued deployment of its "Smell AI" technology across semiconductor and healthcare infrastructure markets — a niche but distinctive positioning in a crowded AI landscape.
The most striking development in the data is how aggressively short interest has unwound. Estimated short positions have fallen nearly 50% over the past month, dropping from roughly 38,000 shares in early April to around 19,600 now. That halving brings SI to just under 0.4% of free float — barely a rounding error at this micro-cap. The retreat began sharply after April 9, when shorts peaked above 43,000 shares. Borrow costs have followed the same direction: cost to borrow peaked near 50% in late March and early April, and has since eased to around 29.6%. Availability is extremely loose at over 1,190% of short interest, meaning there is no meaningful constraint on would-be short sellers entering the stock from here. The borrow market looks relaxed, not stressed.
Insider activity tells a more constructive story. In April, Ainos awarded a combined 1.2 million shares to three insiders — Director Lee Ting-Chuan received 570,000 shares, Director Tsai Chung-Jung received 330,000 shares, and Chairman/President/CEO Tsai Chun-Hsien received 300,000 shares, all at $1.61 per share. Net insider acquisitions over the past 90 days total roughly 1.2 million shares at an implied value of close to $1.9 million. Taiwan Carbon Nano Technology Corporation — which holds 36.4% of the company and is the largest single shareholder — made modest open-market sales earlier in the year, but the net picture across the register remains firmly positive. Director Chiang Yao-Chung has added to his position in small open-market purchases as recently as May 5.
The ownership structure is tightly held. The top three insiders alone account for nearly 60% of shares. Institutional presence is thin outside of the founding bloc — Renaissance Technologies and Two Sigma each hold less than 1% of outstanding shares. With such concentrated ownership, float is limited and liquidity is a real consideration for anyone sizing a position.
There is no analyst coverage visible in the data and no active options market to gauge sentiment. The ORTEX short score sits at 42.5 — broadly neutral on a 0-to-100 scale — consistent with the picture of retreating shorts and ample borrow supply. Peers IMMR and STX both closed lower on Wednesday, suggesting some sector-level pressure, though the correlation with AIMD's closest peers remains modest.
The Q1 filing and the earnings release are now in the public domain. What comes next is whether the Smell AI deployment narrative — and the narrowing losses — attracts any incremental institutional attention to a name that remains almost entirely dominated by its founding shareholders.
See the live data behind this article on ORTEX.
Open AIMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
